Highlights Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Real-time Estimate Cboe Europe Other stock markets 08:00:50 08/05/2024 pm IST			5-day change	1st Jan Change
43.02 ^CHF	+5.71%		+8.59%	+21.81%

03/05	Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024	CI
09/04	Basilea Pharmaceutica Receives Grant for Antibiotics Program	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024	03/05	CI
Basilea Pharmaceutica Receives Grant for Antibiotics Program	09/04	MT
Stocks Close in Green as Swiss Inflation Unexpectedly Slows	04/04	MT
US FDA approves Basilea Pharmaceutica's antibiotic	04/04	RE
US FDA approves Basilea Pharmaceutica's antibiotic	04/04	RE
Continued strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	11/03	DJ
Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2024	13/02	CI
Basilea Pharmaceutica AG Reports Earnings Results for the Full Year Ended December 31, 2023	13/02	CI
Basilea Pharmaceutica Posts Lower FY23 Net Profit; Revenue Up	13/02	MT
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	13/02	DJ
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea	08/02	MT
Cresemba(R) sales in Latin America trigger first sales milestone payment to Basilea	19/01	DJ
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis	15/01	MT
Basilea announces acquisition of preclinical antibiotics program from Spexis	15/01	DJ
Basilea Pharmaceutica Eyes Commercialization Partner for Ceftobiprole Ahead of US FDA Verdict	05/01	MT
Basilea to Get $1 Million Sales Milestone Payment from Pfizer for Antifungal Drug	20/11	MT
Basilea Pharmaceutica Revises Revenue Guidance for the Full Year 2023	13/11	CI
Basilea to Buy Investigational First-in-Class Antifungal Drug from Pfizer Affiliate	13/11	MT
Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON	31/23/31	MT
Basilea Pharmaceutica to Buy Clinical-stage Antifungal Compound from Gravitas Therapeutics	19/23/19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Highlights

Filters